Loading
A phase 3 trial testing Pelabresib, now recruiting.
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib is a phase 3 interventional study registered as NCT06401356, led by Novartis Pharmaceuticals, and recruiting on the registry. Official title: An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib. Planned enrolment is 50 participants (estimated). The study started in 2024-08-13 and primary completion is expected in 2027-06-02. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pelabresib, Novartis.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/